Erythromelalgia Treatment Market Outlook, Trend, Growth and Share Estimation Analysis

Erythromelalgia is a rare condition that primarily affects the feet and it is characterized by intense, burning pain of affected extremities, severe redness (erythema), and increased skin temperature that may be episodic or almost continuous in nature
The specific cause of erythromelalgia remains unknown. Erythromelalgia is a result of vasomotor abnormalities or dysfunction in the normal narrowing and widening of the diameter of certain blood vessels, leading to abnormalities of blood flow to the extremities.
Females are more affected than males. Disorder onset occurs most commonly in middle age; however, associated symptoms may develop at any age. Erythromelalgia is of two types: primary Erythromelalgia and Secondary Erythromelalgia.

Increase in number of patients with erythromelalgia, strong product pipeline, and increasing research & development activity for developing new innovative drugs for treatment of erythromelalgia are likely to drive the erythromelalgia market during the forecast period. In addition, high demand for disease specific novel treatment to the patients as quickly as possible is enhancing the growth of the market.
According to the National Organization for Rare Disorders, prevalence rate of erythromelalgia is approximately 1.3 people in every 100,000 people in the U.S.
On the other hand, limited treatment options and low healthcare budget in some developing countries are likely to restrain the growth of the market

Request a Sample to Get Extensive Insights into the Erythromelalgia Treatment Market

Based on type, the global erythromelalgia treatment market can be segmented into primary erythromelalgia and secondary erythromelalgia
The primary erythromelalgia segment accounted for the highest share of the erythromelalgia treatment market in 2019. This segment is expected to dominate the erythromelalgia treatment market due to high number of patients with erythromelalgia disease.

In terms of treatment type, the global erythromelalgia treatment market can be divided into drug, and surgery. The drug segment is further divided into mexiletine, gabapentin, lidocaine, aspirin, and others.
The drug segment generated the highest revenue in 2019 and is anticipated to witness growth during the forecast period. This can be attributed to strong product pipeline for treatment of erythromelalgia from major manufacturers. Currently, Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals signed a collaboration to develop new product (XEN402) for treatment of erythromelalgia, which is in phase 2.

Based on route of administration, the global erythromelalgia treatment market can be segmented into oral and topical
The oral segment accounted for the highest share of the topical wound agents market in 2019. This segment is expected to dominate the topical wound agents market due to most of the products available in tablet and capsule form and which is more effective as compared to topical dosage form.

In terms of distribution channel, the global erythromelalgia treatment market can be divided into hospital pharmacies, retail pharmacies, and online sales. The retail pharmacies segment generated the highest revenue in 2019 and is anticipated to witness growth during the forecast period due to most of major products are generic products, which is easily available in retail pharmacies.

Looking for Customized Insights to build your Business for Future, Ask for a Custom Report here